Adial Pharmaceuticals enters separation agreement with Dr. Bankole Johnson; consulting termination May 17, 2024

ADIAL PHARMACEUTICALS, INC.

Separation agreement with Dr. Bankole Johnson signed April 22, 2024; consulting termination effective May 17, 2024.
One-time separation fee of $54,375; may continue consulting at $850/hour with prior approval.
Up to $225,000 in milestone payments if certain goals achieved by December 31, 2024.
Agreement includes general release of claims, confidentiality, and mutual nondisparagement.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Bankole A. Johnson

Other

ADIL · ADIAL PHARMACEUTICALS, INC.

Filed: April 26, 2024, 7:59 PM ET

On April 24, 2024, Adial Pharmaceuticals, Inc. (the “Company”) entered into a Separation Agreement and Release, dated April 22, 2024 (the “Separation Agreement”), with Dr. Bankole A. Johnson.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Dr. Bankole A. Johnson departed as other at ADIAL PHARMACEUTICALS, INC..

Action: entered into a Separation Agreement

Exact text from the filing

On April 24, 2024, Adial Pharmaceuticals, Inc. (the “Company”) entered into a Separation Agreement and Release, dated April 22, 2024 (the “Separation Agreement”), with Dr. Bankole A. Johnson.

View on SEC.gov

ADIAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-24-036613

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.